



1/31

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Craig A. Coburn et al.	
Serial No.:	10/541,476	Case No.: 21310YP
Filed:	July 6, 2005	
For:	MACROCYCLIC BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE	


Commissioner for Patents  
P.O. BOX 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

I hereby certify that this correspondence is being deposited with the United States Postal Services as first class mail in an envelope addressed to:  
Commissioner for Patents, P. O. Box 1450,  
Alexandria, VA 22313-1450, on the date appearing Below.

MERCK & CO., INC.  
By  Date 1-21-2006

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits. Accordingly, no fee is due.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By   
John C. Todaro, Reg. No. 36,036  
Attorney for Applicant

MERCK & CO., Inc.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907  
(732) 594-0125

Date: January 26, 2006

**COMPLETE IF KNOWN**

<b>Application Number</b>	10/541,476
<b>Filing Date</b>	July 6, 2005
<b>First Named Inventor</b>	Craig A. Coburn et al.
<b>Group Art Unit</b>	To Be Assigned
<b>Examiner Name</b>	To Be Assigned
<b>Attorney Docket Number</b>	21310YP

(use as many sheets as necessary)

**1**

of

3

Attorney Docket Number 21310YP

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
	A		WO 89/04833		The Upjohn Company	06/01/1989
	B		WO 01/00665		Oklahoma Medical Research Foundation	01/04/2001
					and The Board of Trustees of the	
					University of Illinois	
	C		WO 2003/072535		Elan Pharmaceuticals, Inc.	09/04/2003
	D		EP 1 186 305		Schering Aktiengesellschaft	03/13/2002
	E		WO 02/02512		Elan Pharmaceuticals, Inc. /Pharmacia &	01/10/2002
					Upjohn Company	
	F		WO 03/257721		Elan Pharmaceuticals, Inc. /Pharmacia &	07/17/2003
					Upjohn Company	

Date  
Considered

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

**COMPLETE IF KNOWN**

<b>Application Number</b>	10/541,476
---------------------------	------------

<b>Filing Date</b>	July 6, 2005
--------------------	--------------

<b>First Named Inventor</b>	Craig A. Coburn et al.
-----------------------------	------------------------

Group Art Unit	To Be Assigned
----------------	----------------

Examiner Name	To Be Assigned
---------------	----------------

Attorney Docket Number 21310YP

2

of.

3

Examiner  
Initials\*Cite  
No.

U.S. Patent Document

Number

Kind  
Code  
(if known)Name of Patentee or Applicant  
of Cited Document

Date of Publication of  
Cited Document  
MM-DD-YYYY

Examiner  
Initials\*Cite  
No.

Foreign Patent Document

Office

Number

Kind  
Code  
(if known)Name of Patentee or Applicant  
of Cited Document

Date of Publication of  
Cited Document  
MM-DD-YYYY

**G**

WO 02/100399

E1

Elan Pharmaceuticals, Inc./Pharmacia &
Upjohn Company

12/19/2002

H

WO 02/100856

E

Elan Pharmaceuticals, Inc./Pharmacia &	Upjohn Company
---	----------------

12/19/2002

**Examiner  
Signature**

Date  
Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

## INFORMATION DISCLOSURE

(use as many sheets as necessary)

<b>Application Number</b>	10/541,476
<b>Filing Date</b>	July 6, 2005
<b>First Named Inventor</b>	Craig A. Coburn et al.
<b>Group Art Unit</b>	To Be Assigned
<b>Examiner Name</b>	To Be Assigned
<b>Attorney Docket Number</b>	21310YP

Attorney Docket Number 21310YP

[illegible]

Date Considered

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005